SG11202101298XA - Proteins binding nkg2d, cd16 and a tumor-associated antigen - Google Patents

Proteins binding nkg2d, cd16 and a tumor-associated antigen

Info

Publication number
SG11202101298XA
SG11202101298XA SG11202101298XA SG11202101298XA SG11202101298XA SG 11202101298X A SG11202101298X A SG 11202101298XA SG 11202101298X A SG11202101298X A SG 11202101298XA SG 11202101298X A SG11202101298X A SG 11202101298XA SG 11202101298X A SG11202101298X A SG 11202101298XA
Authority
SG
Singapore
Prior art keywords
tumor
associated antigen
proteins binding
binding nkg2d
nkg2d
Prior art date
Application number
SG11202101298XA
Other languages
English (en)
Inventor
Gregory Chang
Ann Cheung
Jinyan Du
Asya Grinberg
William Haney
Bradley Lunde
Bianka Prinz
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of SG11202101298XA publication Critical patent/SG11202101298XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202101298XA 2018-08-08 2019-08-08 Proteins binding nkg2d, cd16 and a tumor-associated antigen SG11202101298XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862716110P 2018-08-08 2018-08-08
PCT/US2019/045677 WO2020033664A1 (fr) 2018-08-08 2019-08-08 Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur

Publications (1)

Publication Number Publication Date
SG11202101298XA true SG11202101298XA (en) 2021-03-30

Family

ID=69415105

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101298XA SG11202101298XA (en) 2018-08-08 2019-08-08 Proteins binding nkg2d, cd16 and a tumor-associated antigen

Country Status (13)

Country Link
US (1) US20220153848A1 (fr)
EP (1) EP3833385A4 (fr)
JP (1) JP7482363B2 (fr)
KR (1) KR20210078473A (fr)
CN (1) CN113164570B (fr)
AU (1) AU2019318087A1 (fr)
BR (1) BR112021002276A2 (fr)
CA (1) CA3108646A1 (fr)
IL (1) IL280618A (fr)
MA (1) MA53284A (fr)
MX (1) MX2021001527A (fr)
SG (1) SG11202101298XA (fr)
WO (1) WO2020033664A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
WO2023111311A1 (fr) * 2021-12-16 2023-06-22 Universität Basel Variants de protéine de surface cellulaire discernable de cd117 destinés à être utilisés en thérapie cellulaire
WO2024008910A1 (fr) 2022-07-07 2024-01-11 Cimeio Therapeutics Ag Anticorps ciblant cd117

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN107936121B (zh) * 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB2519786A (en) * 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
BR112016024462B1 (pt) * 2014-05-06 2022-12-27 Genentech, Inc Métodos para a preparação de um anticorpo
CN114316061A (zh) * 2015-01-02 2022-04-12 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
CA2990511A1 (fr) * 2015-06-23 2016-12-29 Innate Pharma Proteines qui se lient a des antigenes multispecifiques
US20180327499A1 (en) * 2015-11-13 2018-11-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti- nkg2d single domain antibodies and uses thereof
JP7082604B2 (ja) * 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
CA3090236A1 (fr) * 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Polytherapie de cancer impliquant des proteines de liaison multi-specifiques qui activent des cellules tueuses naturelles

Also Published As

Publication number Publication date
IL280618A (en) 2021-03-25
BR112021002276A2 (pt) 2021-05-04
MX2021001527A (es) 2021-06-15
EP3833385A4 (fr) 2021-12-22
EP3833385A1 (fr) 2021-06-16
MA53284A (fr) 2022-01-26
CN113164570B (zh) 2024-05-14
AU2019318087A1 (en) 2021-03-04
US20220153848A1 (en) 2022-05-19
WO2020033664A1 (fr) 2020-02-13
JP7482363B2 (ja) 2024-05-14
CN113164570A (zh) 2021-07-23
KR20210078473A (ko) 2021-06-28
JP2021533159A (ja) 2021-12-02
CA3108646A1 (fr) 2020-02-13

Similar Documents

Publication Publication Date Title
IL280673A (en) Proteins that bind nkg2d, cd16, and tumor-associated antigen
IL281323A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
IL270803A (en) NKG2D, CD16 and tumor-associated antigen binding protein
IL272706A (en) Proteins that bind D2NKG, 16CD, and tumor-associated antigen
IL270801A (en) NKG2D, CD16 and tumor-associated antigen binding protein
IL268755A (en) HER2, NKG2D, and CD16 binding proteins
IL270794A (en) NKG2D binding protein, CD16 and ROR1 or ROR2
IL280618A (en) Proteins that bind NKG2D, CD16 and tumor-associated antigen
IL268567A (en) BCMA, NKG2D and CD16 binding proteins
IL268790A (en) CD33, NKG2D and CD16 binding proteins
EP3681532A4 (fr) Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)
IL280656A (en) Multispecific binding proteins that bind HER2, NKG2D, and CD16 and methods of use
IL292261A (en) Proteins that bind nkg2d, cd16 and flt3
IL268574A (en) proteins that bind psma, nkg2d, and cd16
SG11202011139YA (en) Protein binding nkg2d, cd16 and a fibroblast activation protein
IL268766A (en) Proteins that bind NKG2D, CD123, and CD16
GB201802338D0 (en) Antigen binding proteins
IL268768A (en) Proteins binding gd2, nkg2d and cd16
IL272374A (en) NKG2D, CD16, and FLT3 binding proteins
EP3847196A4 (fr) Protéines de liaison à un antigène bispécifiques et leurs utilisations
EP3790585A4 (fr) Protéine de liaison au nkg2d, au cd16 et à un antigène associé à une tumeur
IL291364A (en) Antigen binding proteins
ZA201905273B (en) Proteins binding psma, nkg2d and cd16
GB201804531D0 (en) Antigen binding proteins